These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31734605)

  • 1. Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
    Summers MG; Maughan TS; Kaplan R; Law PJ; Houlston RS; Escott-Price V; Cheadle JP
    Eur J Cancer; 2020 Jan; 124():56-63. PubMed ID: 31734605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.
    Smith CG; Fisher D; Harris R; Maughan TS; Phipps AI; Richman S; Seymour M; Tomlinson I; Rosmarin D; Kerr D; Chan AT; Peters U; Newcomb PA; Idziaszczyk S; West H; Meade A; Kaplan R; Cheadle JP
    Clin Cancer Res; 2015 Aug; 21(15):3453-61. PubMed ID: 25873087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
    Innocenti F; Sibley AB; Patil SA; Etheridge AS; Jiang C; Ou FS; Howell SD; Plummer SJ; Casey G; Bertagnolli MM; McLeod HL; Auman JT; Blanke CD; Furukawa Y; Venook AP; Kubo M; Lenz HJ; Parker JS; Ratain MJ; Owzar K
    Clin Cancer Res; 2021 Jan; 27(1):267-275. PubMed ID: 32958699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between 233 colorectal cancer risk loci and survival in 1926 patients with advanced disease.
    Wills C; Houseman A; Watts K; Maughan TS; Fisher D; Houlston RS; West HD; Escott-Price V; Cheadle JP
    BJC Rep; 2023; 1(1):2. PubMed ID: 38665548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients.
    Wills C; He Y; Summers MG; Lin Y; Phipps AI; Watts K; Law PJ; Al-Tassan NA; Maughan TS; Kaplan R; Houlston RS; Peters U; Newcomb PA; Chan AT; Buchanan DD; Gallinger S; Marchand LL; Pai RK; Shi Q; Alberts SR; Gray V; West HD; Escott-Price V; Dunlop MG; Cheadle JP
    Eur J Cancer; 2021 Dec; 159():247-258. PubMed ID: 34794066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer.
    Phipps AI; Newcomb PA; Garcia-Albeniz X; Hutter CM; White E; Fuchs CS; Hazra A; Ogino S; Nan H; Ma J; Campbell PT; Figueiredo JC; Peters U; Chan AT
    Gastroenterology; 2012 Jul; 143(1):51-4.e4. PubMed ID: 22580541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
    Gray V; Briggs S; Palles C; Jaeger E; Iveson T; Kerr R; Saunders MP; Paul J; Harkin A; McQueen J; Summers MG; Johnstone E; Wang H; Gatcombe L; Maughan TS; Kaplan R; Escott-Price V; Al-Tassan NA; Meyer BF; Wakil SM; Houlston RS; Cheadle JP; Tomlinson I; Church DN
    J Natl Cancer Inst; 2019 Aug; 111(8):828-836. PubMed ID: 30649440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CDH1-160C>A polymorphism is a risk factor for colorectal cancer.
    Pittman AM; Twiss P; Broderick P; Lubbe S; Chandler I; Penegar S; Houlston RS
    Int J Cancer; 2009 Oct; 125(7):1622-5. PubMed ID: 19569232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between GWAS-identified genetic variations and disease prognosis for patients with colorectal cancer.
    Kang BW; Jeon HS; Chae YS; Lee SJ; Park JY; Choi JE; Park JS; Choi GS; Kim JG
    PLoS One; 2015; 10(3):e0119649. PubMed ID: 25799222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
    Kap EJ; Seibold P; Scherer D; Habermann N; Balavarca Y; Jansen L; Zucknick M; Becker N; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
    Int J Cancer; 2016 Jun; 138(12):2993-3001. PubMed ID: 26835885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of cyclin D1 (CCND1) and E-cadherin (CDH1) alterations to colorectal cancer susceptibility: a case-control study.
    Govatati S; Singamsetty GK; Nallabelli N; Malempati S; Rao PS; Madamchetty VK; Govatati S; Kanapuram R; Narayana N; Bhanoori M; Kassetty K; Nallanchakravarthula V
    Tumour Biol; 2014 Dec; 35(12):12059-67. PubMed ID: 25146682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal cancer susceptibility loci and influence on survival.
    Song N; Kim K; Shin A; Park JW; Chang HJ; Shi J; Cai Q; Kim DY; Zheng W; Oh JH
    Genes Chromosomes Cancer; 2018 Dec; 57(12):630-637. PubMed ID: 30350386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome.
    Hoskins JM; Ong PS; Keku TO; Galanko JA; Martin CF; Coleman CA; Wolfe M; Sandler RS; McLeod HL
    PLoS One; 2012; 7(7):e41954. PubMed ID: 22848671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single nucleotide polymorphisms within MicroRNAs, MicroRNA targets, and MicroRNA biogenesis genes and their impact on colorectal cancer survival.
    Mullany LE; Herrick JS; Wolff RK; Slattery ML
    Genes Chromosomes Cancer; 2017 Apr; 56(4):285-295. PubMed ID: 27859935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Variants of
    Gaibar M; Galán M; Romero-Lorca A; Antón B; Malón D; Moreno A; Fernández-Santander A; Novillo A
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
    Abraham JP; Magee D; Cremolini C; Antoniotti C; Halbert DD; Xiu J; Stafford P; Berry DA; Oberley MJ; Shields AF; Marshall JL; Salem ME; Falcone A; Grothey A; Hall MJ; Venook AP; Lenz HJ; Helmstetter A; Korn WM; Spetzler DB
    Clin Cancer Res; 2021 Feb; 27(4):1174-1183. PubMed ID: 33293373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
    Arai H; Millstein J; Loupakis F; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mumenthaler SM; Cremolini C; Heinemann V; Falcone A; Lenz HJ
    Eur J Cancer; 2021 Jun; 150():133-142. PubMed ID: 33901792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.